Augmedix, a company that say it turns natural clinician-patient conversation into medical documentation, announced on Wednesday, that Joe Marks, executive director of the Center for Machine Learning & Health at Carnegie Mellon University has been named as the company's new director.
Marks brings to the company extensive experience across such disciplines as artificial intelligence and human-in-the-loop automation. He has run the research labs at both Mitsubishi Electric and The Walt Disney Company. He has worked on DARPA-sponsored research projects for the US government, co-founded two start-ups, and has served as an advisor and consultant to the American Medical Association, all in addition to his current work at Carnegie Mellon. At Augmedix, Marks' official title will be independent director.
Manny Krakaris, chief executive officer at Augmedix, said, 'Augmedix is aggressively pursuing automation innovation in medical note documentation, data aggregation, and analysis. Joe Marks has an established record of pushing technical boundaries of artificial intelligence and machine learning, particularly within health care. We're delighted to have someone of Joe's stature join our team and apply his unique expertise to enhance our efforts in this area.'
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients